José Lopes, PhD

LinkedIn

José holds a PhD in neuroscience from the University of Porto, Portugal. After postdocs at Weill Connell Medicine and Western University, where he studied the processes driving hypertension and Alzheimer’s disease, he moved on in 2016 to a career in science writing and communication. José is the author of several peer-reviewed papers and a book chapter and has presented his research in numerous international meetings.

At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.

Articles by José Lopes, PhD

MYELOMA

FDA Application Submitted for Darzalex Combo Therapy to Treat Certain Multiple Myeloma Patients

An application has been submitted seeking U.S. approval of Darzalex (daratumumab) in combination with standard pre-transplant therapy to treat…

MYELOMA

Darzalex Triple Combo Approved in England for Difficult-to-treat Multiple Myeloma

A triple combination of Darzalex (daratumumab), Velcade (bortezomib), and dexamethasone will be available on the National Health…

MYELOMA

Janssen Seeks Final FDA Approval for Darzalex Combo Therapy for Newly Diagnosed Multiple Myeloma

Janssen has is seeking approval from the U.S. Food and Drug Administration (FDA) for Darzalex (daratumumab) — in combination with…

MYELOMA

Isatuximab Extends Time Without Cancer Progression in Phase 3 Trial of Multiple Myeloma

Adding isatuximab to a standard of care treatment of Pomalyst (pomalidomide) and low-dose dexamethasone prolonged the time without cancer…

MYELOMA

clonoSEQ Assay Now Covered by Medicare for Multiple Myeloma and Acute Lymphoblastic Leukemia

The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow…

MYELOMA

First Patient Treated with Phase 1 Trial Combo of Reolysin, Opdivo, and Kyprolis

A Phase 1 trial of the combination of Reolysin (pelareorep), Kyprolis (carfilzomib), and Opdivo (nivolumab) in relapsed…

MYELOMA

Split Dosing Regimen of Darzalex Approved in Europe for Multiple Myeloma Patients

The European Commission has approved a new dosing regimen of the treatment Darzalex (daratumumab), allowing doctors to split the…

MYELOMA

Aplidin Approved in Australia for Relapsed or Refractory Multiple Myeloma

Treatment with Aplidin (plitidepsin) in combination with dexamethasone was approved in Australia for multiple myeloma patients who have…

MYELOMA

Excessive RNA Editing Linked to Myeloma Progression, Treatment Resistance, Study Suggests

Abnormally high production of an RNA editing enzyme called ADAR1 is associated with multiple myeloma progression and resistance to treatment,…

MYELOMA

Combination of Reolysin, Opdivo, and Standard of Care to Be Tested in Phase 1 Trial for Multiple Myeloma

A combination of Oncolytics Biotech’s investigational therapy Reolysin (pelareorep) with anti-cancer medication Opdivo (nivolumab) and standard of…